EDITORIAL

CONFERENCE REPORTS:
15th Conference on Retroviruses and Opportunistic Infections, 2-6 February 2008, Boston

• Introduction

CROI: ANTIRETROVIRALS

• Atazanavir/r vs lopinavir/r in treatment-naïve patients: 48 week results

CROI: TREATMENT STRATEGIES

• Baseline inflammation and coagulation markers and changes over four weeks during a treatment interruption are strongly linked to HIV viraemia and risk of mortality
• Restarting treatment after an interruption reduces the risk of serious events but CD4 recovery falls short of baseline

CROI: PREGNANCY AND MTCT

• Introduction to MTCT studies
• Very low rate of MTCT in women on HAART in UK and Ireland who achieve viral suppression
• Predictors of mother to child transmission among women initiating HAART in pregnancy in a South African cohort
• Maternal and infant outcomes from the DREAM programme
• Nevirapine-resistant HIV present in the latent reservoir following single-dose nevirapine for MTCT prevention
• Tenofovir plus FTC reduce NNRTI resistance following single dose nevirapine
• Response to treatment after single dose NVP exposure in women
• Response to treatment after single dose NVP exposure in infants
• Other studies looking at birth outcomes
• Infant prophylaxis for postnatal transmission
• Antiretroviral drug concentrations in breast milk and breastfeeding infants
• Maternal breastfeeding prophylaxis
• Risk factors for breastfeeding transmission

CROI: HEPATITIS COINFECTION

• UK cohort reports sexual HCV reinfection in at least 5% HIV-positive gay men following sustained response to treatment
• MELD score predictive of pre-transplant mortality in HIV/HCV coinfected patients
• Does abacavir decrease SVR rates with HCV treatment?
• No effect of interferon maintenance therapy on fibrosis progression in non-responders

CROI: BASIC SCIENCE

• Stem cell transplant from HLA-matched CCR5-delta 32 deleted donor suppresses viraemia in recipient for eight months without HAART

CROI: ONCOLOGY

• Risk factors for AIDS-defining and non AIDS-defining cancers

TREATMENT ACCESS

• FDA approval of generic ARVs; first atazanavir approval
• New PMTCT guidelines for South Africa

ANTIRETROVIRALS

• FDA approve 600mg darunavir tablet
• US study changes use of abacavir/3TC in naïve patients with viral load >100,000 copies based on DSMB recommendation

IMMUNOLOGY AND BASIC SCIENCE

• A gutsy talk, and a new paper: report from third workshop on HIV persistence

OTHER NEWS

• Managing stigma – report into gay and bisexual African men with HIV released

FUTURE MEETINGS

PUBLICATIONS AND SERVICES FROM i-BASE

---

Top | htb | Home | Order & subscribe | Contact | Site map | Access